Plasminogen Activators in the Intestine of Patients with Inflammatory Bowel Disease

Summary

Plasminogen activators were determined in intestinal tissue, obtained after surgery from patients with Crohn’s disease and ulcerative colitis, and compared with normal intestinal tissue from colorectal cancer patients.

The activity and quantity of tissue-plasminogen activator (t-PA) was found to decrease with the severity of inflammation in the patients with inflammatory bowel disease. Urokinase (u-PA) activity, however, was not changed compared with controls or in relation with severity of inflammation. In contrast, the level of u-PA antigen was found to be increased significantly in the inflammatory bowel disease tissues and was also related with severity of inflammation. The difference between u-PA activity and antigen in inflammatory bowel disease tissue could be attributed to an increase in inactive pro-u-PA and u-PA-inhibitor complexes.

This increase in u-PA and the concomitant decrease in t-PA, are similar to those found in premalignant colonic adenomas, and might be related to the known increased cancer risk in inflammatory bowel disease.

Keywords

Crohn’s disease - Intestine - Plasminogen activator - Ulcerative colitis - Urokinase

• References

• 1 Dano K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer.. Adv Cancer Res 1985; 44: 139-267
• 2 Wijngaards G, Jespersen J. Fibrinolytic activity of the gastric mucosa in Ménétrier’s disease.. Eur J Clin Invest 1983; 13: 347-350
• 3 Wong NS, Lau HKF. Demonstration of the presence of plasminogen activator in human small intestine.. Thromb Res 1984; 33: 389-399
• 4 Markus G, Camiolo SM, Kohga S, Madeja JM, Mittelman A. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors. Cancer Res 1983; 43: 5517-5525
• 5 De Bruin PAF, Verspaget HW, Griffioen G, Nap M, Verheijen JH, Lamers C BH W. Plasminogen activator activity and composition in human colorectal carcinomas. Fibrinolysis 1987; 1: 57-62
• 6 Tissot JD, Hauert J, Bachmann F. Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer 1984; 34: 295-302
• 7 Stephens RW, Fordham CJ, Doe WF. Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.. Eur J Cancer Clin Oncol 1987; 23: 213-222
• 8 Elliott R, Stephens RW, Doe WF. Implications of urokinase-type plasminogen activator in the pathogenesis of inflammatory bowel disease (IBD). Gastroenterology 1984; 86: 1069
• 9 Verspaget HW, De Bruin PAF, Weterman IT, Verheijen JH, Nap M, Lamers C BH W. Changes in plasminogen activator activity in inflammatory bowel disease (IBD). Gut 1986; 27: A630
• 10 Lennard-Jones JE, Morson BC, Ritchie JK, Shove DC, Williams CB. Cancer in colitis: assessment of the individual risk by clinical and histological criteria.. Gastroenterology 1977; 73: 1280-1289
• 11 Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JAH, Allan RN. Malignancy in Crohn’s disease.. Gut 1980; 21: 1024-1029
• 12 Kwaan HC, Cocco A, Mendeloff I, Astrup T. Fibrinolytic activity in the normal and inflamed rectal mucosa.. Scand J Gastroenterol 1969; 4: 441-445
• 13 Kondo M, Hotta T, Takemura S, Yoshikawa T, Fukumoto K. Treatment of ulcerative colitis by the direct administration of an antifibrinolytic agent as an enema. Hepato-gastroenterology 1981; 28: 270-273
• 14 Swan CHJ, Alexander WilliamsJ, Cooke WT. Fibrinolysis in colonic disease.. Gut 1970; 11: 588-591
• 15 Salter RF, Read AE. Epsilon-aminocaproic acid therapy in ulcerative colitis.. Gut 1970; 11: 585-587
• 16 Hollanders D, Thomson JN, Schofield PF. Tranexamic acid therapy in ulcerative colitis. Postgr Med J 1982; 58: 87-91
• 17 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma.. Thromb Haemostas 1982; 48: 266-269
• 18 Rijken DC, van Hinsbergh VWM, Sens EHC. Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay.. Thromb Res 1984; 33: 145-153
• 19 Binnema DJ, Van Iersel JJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA.. Thromb Res 1986; 43: 569-577
• 20 Dooijewaard G, Van Iersel JJL, Brommer EJP. Quantitation of pro-UK, UK and UK-inhibitor levels in plasma of patients and healthy men.. Fibrinolysis 1986; 1 suppl 1: 142
• 21 Granelli-Piperno A, Reich E. A study of proteases and proteaseinhibitor complexes in biological fluids.. J Exp Med 1978; 148: 223-234
• 22 Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.. Proc Natl Acad Sei 1983; 80: 6804-6808
• 23 Kwaan HC, Astrup T. Tissue repair in presence of locally applied inhibitors of fibrinolysis. Exp Mol Pathol 1969; 11: 82-88
• 24 Kohga S, Harvey SR, Weaver RM, Markus G. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.. Cancer Res 1985; 45: 1787-1796
• 25 Gelister JSK, Mahmoud M, Lewin MR, Gaffney PJ, Boulos PB. Plasminogen activators in human colorectal neoplasia.. Br Med J 1986; 293: 728-731
• 26 De Bruin PA F, Griffioen G, Verspaget HW, Verheijen JH, Lamers C BH W. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res . 1987; 47: 4654-4657
• 27 De Bruin PA F, Griffioen G, Verspaget HW, Verheijen JH, Dooijewaard G, Van den Ingh HFGM, Lamers C BH W. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 1988; 48: 4520-4524
• 28 Doe WF, Dorsman B. Chronic inflammatory bowel disease - increased plasminogen activator secretion by mononuclear phagocytes.. Clin Exp Immunol 1982; 48: 256-260